https://www.macrotrends.net/stocks/charts/VKTX/viking-therapeutics/total-liabilities
Viking Therapeutics Total Liabilities 2014-2026 | VKTX | MacroTrends
Viking Therapeutics total liabilities from 2014 to 2026. Total liabilities can be defined as the total value of all possible claims against the corporation.
viking therapeuticstotal liabilities20142026vktx
https://www.home.saxo/fr-ch/markets/stocks/vktx-xnas
Viking Therapeutics Inc. action | Saxo Bank Suisse
Viking Therapeutics Inc is a healthcare service provider.
viking therapeuticssaxo bankincactionsuisse
https://www.biospace.com/viking-therapeutics-to-present-at-stifel-healthcare-conference-2020
Viking Therapeutics to Present at Stifel Healthcare Conference 2020 - BioSpace
Nov 10, 2020 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...
viking therapeuticsconference 2020presentstifelhealthcare
https://finviz.com/quote?t=VKTX&ty=dv&ta=1&p=d
VKTX - Viking Therapeutics Inc Dividends
VKTX - Viking Therapeutics Inc - Stock screener for investors and traders, financial visualizations.
viking therapeuticsvktxincdividends
https://www.fool.com/investing/2024/04/02/could-viking-therapeutics-stock-be-a-millionaire-m/
Could Viking Therapeutics Stock Be a Millionaire Maker? | The Motley Fool
Apr 2, 2024 - There is a plausible path for this biotech stock to make some investors millionaires.
viking therapeuticscouldstock
https://www.fool.com/investing/2024/04/28/is-viking-therapeutics-incredibly-undervalued/
Is Viking Therapeutics Incredibly Undervalued? | The Motley Fool
Apr 28, 2024 - The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
viking therapeuticsincrediblyundervaluedmotleyfool
https://www.prnewswire.com/news-releases/viking-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-update-302126602.html
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1%...
2024 financial resultsviking therapeuticsfirst quarter
https://finviz.com/news/343762/viking-therapeutics-to-participate-at-upcoming-investor-conferences
Viking Therapeutics to Participate at Upcoming Investor Conferences
Stock screener for investors and traders, financial visualizations.
viking therapeuticsto participateupcominginvestorconferences
https://www.pissedconsumer.com/company/viking-therapeutics/customer-service.html
Viking Therapeutics Customer Service Phone Number 1-858-704-4660, Email, Help Center
How to contact Viking Therapeutics customer support at phone number? Call or write an email to info@vikingtherapeutics.com to resolve Viking Therapeutics...
https://www.fool.com/investing/2024/09/07/billionaires-are-buying-viking-therapeutics-stock/
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? |...
Sep 7, 2024 - The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock.
https://finviz.com/news/340167/viking-therapeutics-announces-completion-of-enrollment-in-phase-3-vanquish-2-trial-of-vk2735
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
Stock screener for investors and traders, financial visualizations.
https://www.prnewswire.co.uk/news-releases/cordenpharma-and-viking-therapeutics-sign-long-term-strategic-partnership-for-integrated-supply-of-glp-1-peptides-injectables-and-oral-formulations-302397601.html
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of...
https://www.fool.com/investing/2018/06/13/heres-why-viking-therapeutics-rose-as-much-as-149.aspx
Here's Why Viking Therapeutics Rose as Much as 14.9% Today | The Motley Fool
Jun 13, 2018 - The clinical-stage biopharma is on a tear in recent weeks.
https://www.fool.com/investing/2025/04/15/down-71-should-you-buy-dip-on-viking-therapeutics/
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? | The Motley Fool
Apr 15, 2025 - Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?
buy the dip
https://www.prnewswire.com/news-releases/viking-therapeutics-announces-results-from-phase-1b-clinical-trial-of-vk0214-in-patients-with-x-ald-302270769.html
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
https://www.fool.com/investing/2025/04/30/prediction-pfizers-loss-may-be-viking-therapeutics/
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain | The Motley Fool
Apr 30, 2025 - Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
may be